



GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Cwm Taf Morgannwg  
University Health Board



## Freedom of Information Request: Our Reference CTMUHB\_133\_24

### You asked:

Please could you provide me with the information relating to my questions below:

#### **Q1. Please can you provide the name and email address of the medicines management team member who led on the Eye Care (Chapter 11) formulary review when it was last reviewed?**

The Health Board is withholding the name and contact details of the member of staff whose job may fit the title. This decision has been made as it is not within the expectations of the individual that their personal data would be put into the public domain. This information is classed as personal data of third parties and is therefore being withheld in accordance with section 40 (2) of the Freedom of Information Act 2000 (the Act) by virtue of section 40 (3) (a) (i) of the Act which permits a public authority to withhold personal data other than the requester's where the disclosure would breach a Data Protection Principle.

The Data Protection Act 2018 (DPA) / General Data Protection Regulation (GDPR) defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.

Any formulary queries can be sent to [CTM.AccessMeds@wales.nhs.uk](mailto:CTM.AccessMeds@wales.nhs.uk)

#### **Q2. Please can you provide the name and email address of the member of the Health Board Medicines management team who is currently responsible for overseeing Eye Care formularies?**

Please see response to question 1.

#### **Q3. Do you have an area prescribing committee/Medicines Optimisation Committees/ Medicines advisory group or similarly named group that manages your drug formulary decisions?**

Yes. It is called Access to Medicines group.

#### **Q4. Please can you provide the names and email addresses of all members of these formulary groups?**

Please see response to question 1.

#### **Q5. Please can you provide copies of the previous two minutes from the Area Prescribing Committee/ Medicines Optimisation Committees/ Medicines advisory group or similarly named groups meetings?**

Please see attached.

**Q6. I would be grateful if you could confirm for which products within Chapter 11 (Eye) of your formulary, you have a primary care rebate in place, when the agreement commenced, the rebate amount and the end date?**

Please see information provided in the table below. Noting the following:

We can confirm that Cwm Taf Morgannwg University Health Board holds information relating to primary care eye rebates.

However, we would like to advise you that the rebate amount is being withheld under the Freedom of Information Act 2000. The exemption which the Health Board has applied to this information is: Section (43)(2) of the Freedom of Information Act.

The Health Board considers the information to be of a commercially sensitive nature and that the release of this information would or would be likely to prejudice the commercial interests of any parties concerned.

The University Health Board accepts that there is a public interest in ensuring openness and transparency however, the Health Board believes that disclosure of information in a manner which fails to protect the interests and relationships arising in a commercial context could have the effect of discouraging companies from dealing with the Health Board because of fears that the disclosure of information could damage them commercially. In turn this could then jeopardise the Health Boards ability to compete fairly and pursue its function to bring forward development in the area and obtain value for money.

Eye rebates

| Product             | Start date | End date   |
|---------------------|------------|------------|
| Dimaz               | Sept. 2023 | June 2026  |
| Hylofresh           | June 2022  | March 2025 |
| Hylo night ointment | June 2022  | March 2025 |
| Lumecare            | March 2020 | June 2024  |
| Vizidor             | Sept 2023  | June 2025  |
| Xailin              | Sept 2022  | June 2024  |

**Q7. Does the Health Board have a deficit forecast for 2023/2024 financial year? If so, how much is this deficit? And How much is the forecast deficit for 2024/2025 financial year?**

- 23/24 Breakeven
- 24/25 £19.4m

**Q8. What is the value of your Health Boards's planned savings from the Medicines management drug prescribing budget in the financial year: 2023-2024? And 2024 – 2025?**

The only drug prescribing budget sitting in Medicines Management is primary care prescribing. The planned savings for this area are:

- 23/24 £3.314m
- 24/25 £1.104m